Sie suchten nach: t cell defects (Englisch - Estnisch)

regulatory t cell
regulatoorsed t-lümfotsüüdid

increased representation of regulatory t cell subsets
regulatoorsete t-rakkude alarühmade osakaalu suurenemine

cutaneous vasculitis anaphylaxis hepatosplenic t-cell lymphoma
hepatospleeniline t- rakklümfoom

hepatosplenic t-cell lymphoma* (see 4.4)
hepatosplenaalne t-rakuline lümfoom* (vt 4.4)

mean increase in cd4+ t cell (cells/mm3)
cd4+ t-rakkude arvu keskmine suurenemine (rakku/mm3)

a type of lymphoma, called t-cell lymphoblastic lymphoma.
teatud tüüpi lümfoom, mida nimetatakse t- rakuliseks lümfoblastseks lümfoomiks.

no t-cell response to lpl was detected in any subject.
t-rakulist vastust lpl-le ei tuvastatud ühelgi isikul.

a type of leukaemia, called t-cell acute lymphoblastic leukaemia.
teatud tüüpi leukeemia, mida nimetatakse t-rakuliseks ägedaks lümfoblastseks leukeemiaks.

in half of the subjects a t-cell response to the vector was seen.
pooltel patsientidel täheldati t-rakulist vastust vektorile.

t-cell responses were seen in roughly half of the patients without clinical sequelae.
t-rakulist vastust täheldati ligikaudu pooltel patsientidel ilma kliiniliste tagajärgedeta.

not known: merkel cell carcinoma*, hepatosplenic t-cell lymphoma*
teadmata: merkeli raku kartsinoom*, hepatospleeniline t-rakuline lümfoom

this rare type of t-cell lymphoma has a very aggressive disease course and is usually fatal.
see harvaesinev t-rakulise lümfoomi vorm on väga agressiivse kuluga ning üldjuhul fataalne.

responses were seen in different immunophenotypes of all, including pre-b cell and t-cell.
ravivastuseid saavutati all erinevate immunofenotüüpidega, sealhulgas eel-b-rakud ja t-rakud.

ctla-4 inhibits the activity of t cells.
ctla-4 inhibeerib t-rakkude toimet.

sirolimus inhibits t cell activation induced by most stimuli, by blocking calcium dependent and calcium independent intracellular signal transduction.
siroliimus inhibeerib enamiku stiimulite poolt esilekutsutava t- raku aktivatsiooni, blokeerides nii kaltsiumist sõltuvat kui ka kaltsiumist mittesõltuvat rakusisest signaalkaskaadi.

it may also help to increase the number of t cells called cd4 cells.
ta võib ka aidata suurendada t-rakkude arvu, mida nimetatakse cd4-rakkudeks.

activated t cells are the predominant mediators of immunologic response to the transplanted kidney.
aktiveeritud t-rakud on siirdatud neeru vastu tekkiva immuunvastuse peamised vahendajad.

increase of t-cell counts above baseline (t-cell expansion) was observed in few patients.
Üksikutel patsientidel täheldati t-rakkude arvu suurenemist esialgsega võrreldes (t-rakkude vohamist).

some patients who have received tnf-blockers, including flixabi have developed a rare type of cancer called hepatosplenic t-cell lymphoma.
mõnel tnf-blokaatoritega, sh flixabi’ga, ravitud patsiendil, on tekkinud harva esinev vähi tüüp, mida nimetatakse hepatospleeniliseks t-rakuliseks lümfoomiks.

by attaching to the t cells, daclizumab blocks interleukin-2, so preventing t cells from
t-rakkudega seondudes blokeerib daklitsumaab interleukiin-2 toime, takistades sellega t-rakke ründamast ja kahjustamast närvirakke.